US Post News
  • Home
  • Stocks Trading
  • Analyst Snapshot
  • Market Summary
  • Financial Scores
No Result
View All Result
  • Home
  • Stocks Trading
  • Analyst Snapshot
  • Market Summary
  • Financial Scores
No Result
View All Result
US Post News
No Result
View All Result

Phathom Pharmaceuticals Inc. (NASDAQ:PHAT): It’s all about numbers this morning

April 4, 2023
in Industry

Phathom Pharmaceuticals Inc. (PHAT)’s stock is trading at $7.73 at the moment marking a rise of 4.18% from the last session close. As of this writing, shares are priced at -51.89% less than their 52-week high of $16.07, and 32.36% over their 52-week low of $5.84. Based on the past 30-day period, the stock price is -11.81% below the high and +34.25% above the low.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.

Sponsored

The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, PHAT’s SMA-200 is $9.46.

How does Phathom Pharmaceuticals Inc. (PHAT) stock rate among analysts? Buy, sell, or hold?

The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 7 brokerage firms that recommend the stock as a Moderate Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.29 in simple terms.

Phathom Pharmaceuticals Inc. (PHAT): Earnings History

If we examine Phathom Pharmaceuticals Inc.’s recent earnings history, in the last quarter ended on 12/30/2022, it posted adjusted earnings per share of -$1.33, slashing the consensus of -$1.35. In other words, it beat the consensus by $0.02, resulting in a 1.50% surprise. In the 3 months period before the previous quarter which was closed on 12/30/2022, the stock recorded adjusted earnings per share of -$1.33 in contrast with the Outlook of -$1.35. That was a difference of $0.02 and a surprise of 1.50%.

Phathom Pharmaceuticals Inc. (PHAT): Earnings History

Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 1 different analysts, who are expecting earnings to fall in between the range of -1.34 and -1.34 with an average Earnings Estimate of -1.34 which is in contrast with the last year earnings estimate of -1.07 and also replicates -25.23% growth rate year over year.

Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) Ownership Details

I will give a breakdown of the key shareholders in Phathom Pharmaceuticals Inc. (PHAT). Recent figures show that the company’s insiders hold 23.29% of shares. A total of 146 institutional investors hold shares in the company, making 73.61% of its stock and 95.96% of its float.

Dec 30, 2022, it was reported that the Company’s largest institutional holder is Frazier Life Sciences Management, L.P. holding total of 8.41 million shares that make 20.03% of the company’s total number of shares and are currently priced at 65.16 million.

The securities firm Medicxi Ventures Management (Jersey) Ltd holds 2.48 million shares of PHAT, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 5.92%, and the holding percentage of shares is valued at 19.25 million.

An overview of Phathom Pharmaceuticals Inc.’s technicals

In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Phathom Pharmaceuticals Inc. (PHAT) traded 380,645 shares per day, with a moving average of $6.98 and price change of -0.35. With the moving average of $8.86 and a price change of -0.90, about 399,772 shares changed hands on average over the past 50 days. Finally, PHAT’s 100-day average volume is 324,655 shares, alongside a moving average of $9.32 and a price change of -2.09.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

A stock that deserves closer examination: CVR Energy Inc. (CVI)

April 26, 2023

It would be worthwhile to take a closer look at ReShape Lifesciences Inc. (RSLS)

April 20, 2023

What to expect from ADMA’s earnings report this quarter?

May 15, 2023

“US Post News” – one of the oldest and most authoritative news sites in America. It was established in 1992, journalists, photographers, correspondents, researchers came to the publication from the editorial offices of regional newspapers, drama theater, etc. They had no training, and they gained experience and skill in the process of work.

Contact us: ceo@www.uspostnews.com

Catagories

  • Market Summary
  • Stocks Trading
  • Analyst Snapshot
  • Financial Scores

Company

  • Home
  • About US
  • Contact US

RECENT POSTS

  • Open Lending Corporation (LPRO) stock analysis: A simple moving average approach
  • Wolfspeed Inc. (WOLF)’s highs and lows: A closer look at its stock price fluctuations
  • A year in review: Seacoast Banking Corporation of Florida (SBCF)’s performance in the last year

Copyright © 2022 US Post News

No Result
View All Result
  • About US
  • Contact US
  • Home

Copyright © 2022 US Post News